Radiopharm Theranostics Limited American Depositary Shares · PINK
$2.11+0.03 (+1.44%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Radiopharm Theranostics Limited American Depositary Shares, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $16.00 to $16.00, so the covering firms are broadly aligned. The average target of $16.00 sits 658% above the current $2.11. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees revenue growth near -100% this year and 0% next.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Radiopharm Theranostics Limited American Depositary Shares.
As of Sep, 2 of 2 firms rate RADX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RADX EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 1 analysts
Next period, 1 analysts expect Radiopharm Theranostics Limited American Depositary Shares to earn — a share (range — – —), versus — a year earlier. Full-year consensus is $-3.23, growing to $-2.64 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $1.1M, rising to $23.8M next year.
Top analysts covering Radiopharm Theranostics Limited American Depositary Shares
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RADX.
#1
RB
Robert Burns
HC Wainwright & Co. · Rank #199
Buy
$16.00+658.3% to target
Overall win rate
41%
+ Follow
#2
YZ
Yuan Zhi
B. Riley Securities
Buy
$16.00+658.3% to target
Coverage
—
+ Follow
#3
Michael Okunewitch
Maxim Group
Buy
$15.00+610.9% to target
Coverage
—
+ Follow
#4
JW
Justin Walsh
JonesTrading
Buy
$30.00+1321.8% to target
Coverage
—
+ Follow
#5
KD
Kemp Dolliver
Brookline Capital
Buy
$18.00+753.1% to target
Coverage
—
+ Follow
RADX stock forecast FAQ
What is RADX's average 12-month price target?+
The 2 analysts with a live target average $16.00 for Radiopharm Theranostics Limited American Depositary Shares over the next 12 months, ranging from a $16.00 high to a $16.00 low.
Is RADX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover RADX?+
2 analysts have an active rating on Radiopharm Theranostics Limited American Depositary Shares, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering RADX?+
Among analysts who currently cover RADX, Robert Burns of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #199). Their current call is Buy with a $16.00 target.
What is Radiopharm Theranostics Limited American Depositary Shares's projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 1 analysts. Full-year EPS is projected at $-3.23, rising to $-2.64 the following year.
How much revenue is Radiopharm Theranostics Limited American Depositary Shares expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $1.1M, growing to $23.8M next year.
Have analysts been upgrading or downgrading RADX lately?+
As of Sep, 2 of 2 firms rate RADX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RADX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
